Replimune Group Inc REPL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
-
Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward
-
Replimune Disputes FDA Rejection of Skin Cancer Treatment, Criticizes Review Process
-
FDA Rejects Replimune's Melanoma Drug for a Second Time
-
Replimune Shares Soar After FDA Accepts Melanoma Treatment Resubmission
Trading Information
- Previous Close Price
- $8.62
- Day Range
- $8.56–9.27
- 52-Week Range
- $1.50–13.24
- Bid/Ask
- $8.79 / $8.90
- Shares Outstanding
- 82.57M
- Market Cap
- $733.24M
- Volume/Avg
- 2M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 11.82%
Company Profile
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 479
- Website
- https://www.replimune.com
Valuation
|
Metric
|
REPL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.26 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
REPL
|
|---|---|
Quick Ratio | 5.43 |
Current Ratio | 5.60 |
Interest Coverage | −38.57 |
Quick Ratio
REPL
Profitability
|
Metric
|
REPL
|
|---|---|
Return on Assets (Normalized) | −60.57% |
Return on Equity (Normalized) | −83.21% |
Return on Invested Capital (Normalized) | −66.13% |
Return on Assets
REPL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ljhxmwzry | Wjfkp | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Thkyhbhg | Gjfymgw | $64B | |||
| argenx SE ADR
ARGX
| Xywnjrh | Qkfh | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dqyvrdzd | Skvbw | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Drpcrcysr | Hyfsw | $24B | |||
| BioNTech SE ADR
BNTX
| Ggqnzrtls | Krd | $23B | |||
| Incyte Corp
INCY
| Vzmjlss | Jzth | $22B | |||
| Moderna Inc
MRNA
| Hldgynjk | Fgw | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qnzdkvyz | Npkn | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Lkmbjzggl | Cnwt | $13B |
United States